Your browser is no longer supported. Please, upgrade your browser.
Settings
SLNO Soleno Therapeutics, Inc. daily Stock Chart
SLNO [NASD]
Soleno Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own17.50% Shs Outstand32.69M Perf Week-7.83%
Market Cap50.02M Forward P/E- EPS next Y-0.77 Insider Trans- Shs Float26.24M Perf Month-15.93%
Income-19.00M PEG- EPS next Q-0.16 Inst Own57.90% Short Float1.53% Perf Quarter-44.96%
Sales- P/S- EPS this Y-329.90% Inst Trans- Short Ratio11.15 Perf Half Y-24.26%
Book/sh0.44 P/B3.48 EPS next Y10.60% ROA-53.10% Target Price12.00 Perf Year-19.47%
Cash/sh0.49 P/C3.11 EPS next 5Y- ROE-95.10% 52W Range1.11 - 5.07 Perf YTD-10.53%
Dividend- P/FCF- EPS past 5Y26.70% ROI- 52W High-69.82% Beta2.22
Dividend %- Quick Ratio5.80 Sales past 5Y- Gross Margin- 52W Low37.84% ATR0.12
Employees12 Current Ratio5.80 Sales Q/Q- Oper. Margin- RSI (14)40.55 Volatility5.27% 8.24%
OptionableNo Debt/Eq0.00 EPS Q/Q3.40% Profit Margin- Rel Volume1.04 Prev Close1.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume35.94K Price1.53
Recom2.00 SMA20-8.52% SMA50-13.98% SMA200-25.22% Volume37,498 Change3.38%
Feb-13-18Reiterated Maxim Group Buy $8 → $4
Oct-02-19 08:00AM  Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome GlobeNewswire +15.54%
Oct-01-19 02:22PM  We Think Soleno Therapeutics (NASDAQ:SLNO) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-24-19 08:00AM  Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire
Sep-19-19 08:00AM  Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies GlobeNewswire -5.49%
Aug-07-19 04:05PM  Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 01:19PM  Did Changing Sentiment Drive Soleno Therapeutics's (NASDAQ:SLNO) Share Price Down By 44%? Simply Wall St.
08:00AM  Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome GlobeNewswire
Jul-15-19 09:00AM  Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know Zacks
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
Jul-01-19 08:39AM  La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza Zacks
Jun-12-19 08:00AM  Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors GlobeNewswire
May-28-19 06:07AM  Will Capnia to Surge Higher? Zacks +6.28%
May-24-19 08:49AM  What Kind Of Shareholders Own Soleno Therapeutics, Inc. (NASDAQ:SLNO)? Simply Wall St.
May-13-19 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
08:11AM  Small Drug Stocks Outlook: Near-Term Prospects Encouraging Zacks
Apr-29-19 08:00AM  Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors GlobeNewswire
Apr-03-19 08:00AM  Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire +5.56%
Mar-27-19 08:46AM  Will Capnia Continue to Surge Higher? Zacks -6.42%
Mar-25-19 10:00AM  Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice Zacks
08:00AM  Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference GlobeNewswire
Mar-20-19 07:48AM  Soleno Therapeutics Inc (SLNO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -10.09%
Mar-18-19 08:30AM  Soleno Therapeutics, Analyst Review and Pipeline Progress ACCESSWIRE
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Mar-15-19 04:05PM  Four Healthcare Stocks Picking Up Speed On Friday ACCESSWIRE +98.52%
03:00PM  Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today InvestorPlace
07:39AM  The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA Benzinga
Mar-14-19 05:32PM  Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome Business Wire
Mar-11-19 04:05PM  Soleno Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
Dec-19-18 04:01PM  Soleno Therapeutics Announces $16.5 Million Private Placement GlobeNewswire
Dec-12-18 06:47AM  Is Soleno Therapeutics, Inc.s (NASDAQ:SLNO) CEO Pay Justified? Simply Wall St. -8.14%
Nov-15-18 08:05AM  Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018 GlobeNewswire
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-08-18 08:00AM  Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference GlobeNewswire -11.31%
Oct-01-18 08:00AM  Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology GlobeNewswire +5.09%
Sep-19-18 08:00AM  Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease GlobeNewswire
Sep-17-18 08:00AM  Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology GlobeNewswire
Sep-06-18 08:00AM  Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients GlobeNewswire
Sep-04-18 08:00AM  Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome GlobeNewswire
Aug-14-18 04:05PM  Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 08:00AM  Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire +8.66%
Jun-04-18 08:00AM  Soleno Therapeutics To Present Corporate Update at the BIO International Convention GlobeNewswire
May-16-18 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-14-18 08:00AM  Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome GlobeNewswire +20.25%
Apr-03-18 06:15PM  What Should You Know About Soleno Therapeutics Incs (NASDAQ:SLNO) Future? Simply Wall St.
Apr-02-18 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
Mar-26-18 08:48PM  Does Soleno Therapeutics Incs (NASDAQ:SLNO) Past Performance Indicate A Weaker Future? Simply Wall St.
Mar-16-18 06:14PM  Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near? Simply Wall St.
Feb-20-18 08:00AM  Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome GlobeNewswire
Dec-12-17 08:30AM  Soleno Therapeutics Announces $15 Million Private Placement GlobeNewswire
Dec-11-17 08:10AM  Todays Research Reports on Stocks to Watch: Soleno Therapeutics and La Jolla Pharmaceutical Company ACCESSWIRE
Dec-08-17 05:43PM  Is Soleno Therapeutics Incs (SLNO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +10.97%
08:00AM  Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology GlobeNewswire
Nov-30-17 03:15PM  Should Soleno Therapeutics Incs (SLNO) Earnings Decline In Recent Times Worry You? Simply Wall St.
Nov-22-17 08:00AM  Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-14-17 03:59PM  What Is Soleno Therapeutics Incs (SLNO) Share Price Doing? Simply Wall St. -12.08%
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-23-17 08:00AM  Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements GlobeNewswire
Oct-12-17 08:00AM  Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome GlobeNewswire
Oct-11-17 08:00AM  Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome GlobeNewswire +7.98%
Oct-05-17 01:00PM  Soleno Therapeutics Announces 1-for-5 Reverse Stock Split GlobeNewswire
Sep-25-17 08:00AM  Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome GlobeNewswire
Sep-12-17 03:37PM  Before You Buy Soleno Therapeutics Incs (SLNO), You Should Consider This Simply Wall St.
Aug-24-17 11:22AM  Soleno Therapeutics, Inc. :SLNO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. It has collaboration agreement with Casimir Inc. to develop DCCR tablets for patients with PWS. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.